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Abstract
Background: Severe gait disturbances in idiopathic Parkinson’s disease (PD) are observed in up to 80% of all
patients in advanced disease stages with important impact on quality of life. There is an unmet need for further
symptomatic therapeutic strategies, particularly as gait disturbances generally respond unfavourably to
dopaminergic medication and conventional deep brain stimulation of the subthalamic nucleus in advanced disease
stages. Recent pathophysiological research pointed to nigro-pontine networks entrained to locomotor integration.
Stimulation of the pedunculopontine nucleus is currently under investigation, however, hitherto remains
controversial. The substantia nigra pars reticulata (SNr) - entrained into integrative locomotor networks - is
pathologically overactive in PD. High-frequent stimulation of the substantia nigra pars reticulata preferentially
modulated axial symptoms and therefore is suggested as a novel therapeutic candidate target for
neuromodulation of refractory gait disturbances in PD.
Methods: 12 patients with idiopathic Parkinson’s disease and refractory gait disturbances under best individual
subthalamic nucleus stimulation and dopaminergic medication will be enroled into this double-blind 2 × 2 cross-
over clinical trial. The treatment consists of two different stimulation settings using (i) conventional stimulation of
the subthalamic nucleus [STNmono] and (ii) combined stimulation of distant electrode contacts located in the
subthalamic nucleus and caudal border zone of STN and substantia nigra pars reticulata [STN+SNr]. The primary
outcome measure is the change of the cumulative ‘axial score’ (UPDRS II items ‘13-15’ and UPRDS III items ‘27-31’)
at three weeks of constant stimulation in either condition. Secondary outcome measures include specific scores on
freezing of gait, balance function, quality of life, non-motor symptoms, and neuropsychiatric symptoms. The aim of
the present trial is to investigate the efficacy and safety of a three week constant combined stimulation on [STN
+SNr] compared to [STNmono]. The results will clarify, whether stimulation on nigral contacts additional to
subthalamic stimulation will improve therapeutic response of otherwise refractory gait disturbances in PD.
Trial registration: The trial was registered with the clinical trials register of http://www.clinicaltrials.gov
(NCT01355835)
Keywords: balance, deep brain stimulation (DBS), freezing of gait (FOG), gait disturbance, interleaved pulses, Par-
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Background
Refractory gait disturbances in Parkinson’s disease
Severe gait disturbances in idiopathic Parkinson’s dis-
ease are observed in up to 80% of the patients in
advanced disease stages [1,2] with important impact on
quality of life [3-5]. Therapeutic deep brain stimulation
of the subthalamic nucleus (STN-DBS) as an evidence-
based therapy [6-8] generally ameliorates segmental
symptoms and motor fluctuations, whereas axial symp-
toms and in particular gait disturbances may respond
unfavourably and generally aggravate in parallel with
the underlying neurodegeneration [9,3,10]. In this con-
dition, increasing intensity of high-frequent STN-DBS
at 130 Hz even worsens the condition [10]. Currently,
several approaches are under investigation in order to
address the therapeutic need for gait disturbances
refractory to dopaminergic treatment and STN-DBS.
STN-DBS on lower frequencies, e.g. at 60 Hz can
improve gait disturbances, however is limited by the
recurrence of segmental symptoms like tremor, brady-
kinesia and rigidity [10]. Stimulation of the pedunculo-
pontine area for refractory gait disturbances remains
controversial at the moment [11-13], however several
experimental lines of evidence demonstrated the inte-
grative role of reciprocal brainstem circuitries includ-
ing substantia nigra pars reticulata (SNr) and the
pedunculopontine area [14-16]. Importantly, activity of
the SNr can be modulated after implantation for con-
ventional STN-DBS, as the caudal electrode contacts
are generally located in the caudal border zone of STN
and SNr [17,18].
Simultaneous stimulation of STN and SNr with interleaved
pulses: uncovering of a novel stimulation paradigm for
refractory gait disturbances?
At present, stimulation impulses are generally delivered
on single monopolar contacts polarised against the gen-
erator case or between bipolar adjacent electrode con-
tacts. Recently, the advancement of the implantable
impulse generators enabled the novel paradigm of the
so-called ’interleaved pulses’, i.e. stimulation impulses
are delivered simultaneously on two different contacts
in alternating order. Importantly, each of the contacts
can be programmed onto specific parameters (ampli-
tude, pulse width) at a common stimulation frequency
(e.g. 125 Hz on each contact). This might allow for (i)
optimization of the stimulation settings by minimizing
side effects from current spreading to the vicinity of the
STN (especially if stimulation on a second monopolar
contact is necessary to achieve sufficient therapeutic
effects without inducing side effects), and (ii) improved
therapeutic efficacy by delivering the stimulation pulses
more selectively on different and distant contacts,
although both issues remain to be demonstrated in clin-
ical studies.
In our center for deep brain stimulation electrodes in
STN-DBS surgery are generally placed with the upper-
most contact of the quadripolar electrode located in the
rostral border zone of zona incerta and STN and the
lowermost contact in the caudal border zone of STN
and SNr. This neuroanatomic assumption is substan-
tiated by several common intra- and postoperative find-
ings: (i) efficacy of a proximal contact on segmental
symptoms like rigidity or tremor and a facultative induc-
tion of dyskinesias on the respective contact (upon
increasing energy delivery) indicates its localisation in
the dorsolateral STN motor area; (ii) intraoperative sin-
gle cell recordings often identify bursting STN activity
followed by regular tonic discharge when the descending
microelectrode is leaving STN and entering SNr [19].
The novel paradigm using “interleaved pulses” therefore
enables simultaneous stimulation with specific para-
meters of both STN area and the caudal STN/SNr bor-
der zone.
Objectives
We hypothesize that simultaneous stimulation on con-
tacts located in both STN and caudal STN/SNr border
zone [STN+SNr-DBS] improves gait disturbances com-
pared to conventional STN-DBS delivered on a single
contact located in the STN area [STNmono].
➢ To test the hypothesis that [STN+SNr-DBS] is
more effective on hypokinetic gait disturbances com-
pared to [STNmono] in a randomised double-blind
cross-over three week follow-up.
➢ To evaluate the short term effects of the condi-
tions [StimOff], [STNmono] and [STN+SNr] on
hypokinetic gait disturbances.
➢ To assess the impact of combined [STN+SNr-
DBS] on further specific gait and balance features
including freezing of gait in particular, as well as
further non-motor features of Parkinson’s disease in
terms of quality of life, non-motor and neuropsy-
chiatric symptoms as secondary endpoints.
Design and Methods
This double-blind randomised cross-over clinical trial
consists of two arms. Severity of the gait disturbance
will be assessed after a three week follow-up of both
(i) conventional stimulation of the STN area
[STNmono] and (ii) combined stimulation of the STN
area and the caudal STN/SNr border zone [STN+SNr].
12 consecutive patients will be randomised on blocks
to the two treatment conditions in a 1:1 ratio and
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treatments will be crossed-over after three weeks of
follow-up, respectively. Moreover, a baseline assess-
ment ’off dopaminergic medication’ will be performed
in order to assess short-term effects and to assure
optimal stimulation parameters of the conventional
STN-DBS [STNmono]. A composite ‘axial score ’
including the major clinical and anamnestic items on
gait, posture and balance function from UPDRSII
(items 13-15) and UPDRS III (items 27-31) constitutes
the primary outcome measure.
Population and Recruitment
The patient population will consist of patients with
refractory gait disturbances and advanced Parkinson’s
disease treated with STN-DBS with implanted impulse
generators that allow for the delivery of “interleaved
pulses” (ACTIVA PC, ACTIVA RC). Patients will be
recruited at the Center of Neurology, Tübingen
University.
Inclusion criteria
• Written informed consent
• Age: between 18 and 80 years
• Idiopathic Parkinson’s disease (according to the
“British Brain Bank criteria” [20] including genetic
forms and therapy with STN-DBS (ACTIVA pulse
generator)
• Optimized subthalamic stimulation (refer ‘treat-
ment’ section)
• Gait disturbance refractory to best individual STN-
DBS (STNmono) and dopaminergic therapy: compo-
site ’axial score’ in the best clinical [MedOn/
STNmono] condition ≥ 12
• Clinical and image-guided or electrophysiological
confirmation of (i) at least one of the two rostral
contacts of the quadripolar electrode localized in the
STN area.
• Dopaminergic medication constant for at least four
weeks prior to study enrolment
• Implantation of the DBS electrodes at least 6
months before study enrolment
• Disease duration ≥ 5 years
Exclusion criteria
• Cognitive impairment (Mini Mental State Exam <
25)
• Participation in other clinical trials within the past
three months and during enrolment in our study
• Suicidality, Psychosis
• Other severe pathological chronic condition that
might confound treatment effects or interpretation
of the data
• Pregnancy
• Acute adverse effects from stimulation on contacts
in the caudal STN/SNr border zone
Screening
Patients will be recruited at the Department for Neuro-
degenerative Diseases of the Center of Neurology, Uni-
versity of Tübingen, Germany. A neurologist will assess
the eligibility of a patient according to the inclusion and
exclusion criteria as detailed above.
Safety
Endpoints of safety are • Death
• Severe symptomatic exacerbation of the pre-existing
gait disturbance, defined by repetive falls (if not preexi-
stant) due to aggravated freezing of gait or imbalance
(UPDRS II, items 13-14, UPDRS III, item 30)
• Newly occurring or aggravated depressive symptoms
(BDI), suicidality (BDI, item 9), impulsivity (Barrett
impusivity scale), hallucinatory behaviour and psychosis
(UPDRS I, item 2).
• worsening of segmental motor symptoms (UPDRS
III, items 20-26) or motor fluctuations (UPDRS IV)
Information about these safety parameters is recorded
in the CRF.
Outcome measures
The primary outcome measure is defined as the differ-
ence of the composite ‘axial score’ including the major
UPDRS II and III items of gait, balance and posture
after three weeks of double-blind treatment with either
(i) conventional [STNmono] or (ii) combined [STN
+SNr-DBS]. The secondary efficacy variables enable a
differentiated assessment of specified axial symptoms,
namely freezing of gait (including provoking man-
oeuvres), gait velocity, clinical balance testing, neuropsy-
chiatric symptoms, and non-motor symptoms.
Study protocol
Clinical testings at baseline will be performed after over-
night withdrawal of dopaminergic medication and after
optimization of subthalamic stimulation. Follow-up
examinations will be performed in the ’dopaminergic on
state’. Of note, no follow-up examinations with a single
active SNr contact will be conducted as this previously
failed to control for segmental symptoms like tremor,
bradykinesia and rigidity [17].
Figure 1: Baseline testings will be performed “off dopa-
minergic medication” after overnight withdrawal with (i)
[StimOff], (ii) [STNmono], and (iii) [STN+SNr]. On vis-
its 1 and 2, we will assess the treatment effects of
[STNmono] and [STN+SNr] after three weeks of con-
stant stimulation on either setting. The order of the
treatment conditions will be randomized and crossed
after the first visit. Randomisation lists for the different
treatment conditions are prepared by the Department of
Medical Biometry.
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Withdrawal from the study
In case of endangerment of personal safety or lack of
compliance or withdrawal of informed consent, a patient
will instantly be excluded from further participation in
the study.
Sample size calculation and statistical analysis plan
Primary Endpoint
The primary endpoint for the statistical evaluation of
the therapy is the change in composite ‘axial score’. The
‘axial score’ is built by 8 items from the UPDRS II and
III, all 5-point rated. For the statistical evaluation the
five rating points are represented by the numbers 0 to 4,
which represent increasing levels of pathology. The
‘axial score’ will be scored by the sum of the ratings
across the 8 items (range 0 to 32). As change in UPDRS
scores is a common primary efficacy outcome measure
in Parkinson’s disease and only items of the original
UPDRS are required for the definition of the primary
endpoint the statistical evaluation methods should be
based on the psychometric validation of the UPDRS and
no own validation studies are necessary.
The primary endpoint for the statistical evaluation will
be the change in ‘axial score’ from baseline to visit 2
(after 6 weeks). For every patient we will determine two
change-scores for the two phases in the Cross-Over. By
means of a paired t-test the null hypothesis of equality
of the two therapies concerning the change in ‘axial
score’ will be tested. The decision for maintaining or
rejecting the null hypothesis will be made applying a
two-sided test with a = 0.05. The observed effects will
be described by use of means and effect sizes including
the appropriate 95%-confidence intervals. The confirma-
tory statistical evaluation of the efficacy of the [STN
+SNr-DBS] in this trial will be restricted to the primary
endpoint. Only the rejection of the null hypothesis will
be interpreted as statistical evidence for the efficacy of
[STN+SNr-DBS].
As no comparable study is available at the moment,
we defined an improvement of 4 points on the primary
outcome measure ‘axial score’ to be clinically relevant
on hypokinetic gait disturbances and assumed a stan-
dard deviation of 4.0 (effect size: 1.0). A sample size of
10 will have 80% power to detect a difference in means
of 4.0 (e.g. first condition mean: 16.0 and a second con-
dition mean of 12.0), using a paired t-test with a 0.05
two-sided significance level (sample size estimated using
NQuery Advisor 7.0). To adjust for a maximum of two
dropouts a total of n = 12 patients will be included in
the study.
Secondary Endpoints
As all secondary endpoints are based on validated
scores, we assume that parametric statistical methods
can be used for the analysis. The secondary endpoints
will be compared and statistically assessed for descrip-
tive purposes and not in a confirmatory sense. The aim
is explorative data analysis, not hypothesis testing or
generation of evidence for efficacy. Because of the
explorative character of this part of the analysis, no a
priori statistical analysis plan exists. If adequate, changes
of scores over time will be analysed with paired t-tests
or appropriate statistical methods (eg. Repeated Mea-
surements Anova). If a categorization of scores should
be adequate (eg. classification in success vs. failure
according to score-cut-offs) we will use adequate analy-
sis methods for categorical variables (eg. McNemar
Test). In addition, appropriate statistical methods of
explorative data analysis including graphical methods
and descriptive statistics will be used. No interim analy-
sis and no subgroup analysis are planned.
Handling of Missing Data
All variables included in the CRF are mandatory. The
monitoring will assure quality of the assessments. Thus,
missing values are to be expected (eg. refusal of
patients). Patients with missing values for the primary
endpoint will be included with the last observed score
Figure 1 Study design.
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before the planned time point (last-observation-carried-
forward). All randomised patients will be included
(Intention-to-treat).
Randomisation
A randomisation list was prepared by the Department of
Medical Biometry of the University Hospital of
Tübingen.
Treatment
Optimization of subthalamic stimulation is mandatory
prior to study enrolment. Based on the current knowl-
edge for optimized DBS programming (i) gait distur-
bances emerge and progress in the first years after
introduction of subthalamic stimulation [9], (ii) a
further increase of the stimulation amplitudes may even
aggravate the gait disturbance [10], and (iii) the stimula-
tion intensity of the lower extremity with longer step
length should be reduced compared to the worse
affected side - this was previously demonstrated to ame-
liorate gait symmetry with benefitial effects to gait dis-
turbances, presumably freezing of gait [21]. These
actions will be taken before considering combined [STN
+SNr] stimulation, however, even if applied a substantial
proportion of patients continues to exhibit refractory
gait disturbances.
After written informed consent and screening for
inclusion criteria, patients will be examined in the base-
line condition ‚off dopaminergic medications’ in order to
assure optimization of the best individual stimulation
parameters of the conventional STN stimulation
[STNmono] and to determine the short-term effects of
either stimulation setting. The [STN+SNr] condition
will consist of the [STNmono] parameters and addi-
tional simultaneous stimulation with interleaveing pulses
on a distal contact with best individual amplitude, 60 μs
pulse width, and 125 Hz frequency will be introduced
depending on individual thresholds for side effects from
current spreading. In the baseline examination a rando-
mised clinical evaluation of the treatment conditions
[StimOff], [STNmono], and [STN+SNr] in terms of
short term effects will be performed.
After the baseline examination, patients will be rando-
mised to either [STNmono] or [STN+SNr] treatment
and scheduled at three weeks of constant stimulation
(Visit 1). After this first endpoint assessment treatment
will be crossed-over and patients will be re-scheduled
after further three weeks of constant stimulation for the
second endpoint assessment (Visit 2). The follow-up
period is - due to the current clinical evidence - suffi-
ciently long to control adequately for carry-over effects
since the endpoint assessment in the follow-up period
will be scheduled only after three weeks of constant sti-
mulation on either setting. STN-DBS in PD generally
evokes clinical effects within short time intervals ranging
from several seconds to few hours and presents comple-
tely reversible in the same time range. In the first
patient described with improvement from [STN+SNr]
compared to [STNmono], the clinical superiority of
[STN+SNr] was demonstrated after 30 minutes of con-
stant stimulation on either setting [18], and monopolar
stimulation on STN or SNr contacts revealed discrimin-
able clinical effects on segmental and axial symptoms if
both settings were applied randomly within one day in
an independent study [17]. Dopaminergic medication
will be held constant during the whole six week cross-
over period and should be stable for at least 4 weeks
before study enrolment.
Importantly, we did not consider stimulation on a sin-
gle monopolar contact in the SNr area in our study
design as this failed to improve segmental symptoms
previously [17], and therefore is not applicable for ade-
quate management of Parkinsonian motor symptoms.
Blinding
The endpoint assessor remains masked to the treatment
until the final data analysis. In order to limit potential
patients’ knowledge on the stimulation parameters, sti-
mulation parameters will be strictly kept subthreshold
for side-effects. The parameters will be changed several
times between [STNmono] and [STN+SNr] before the
parameters of interest are maintained. Patients and end-
point assessor will be blinded to both short-term test-
ings and follow-up visits, so that a possible clinical
improvement of gait on either setting will remain unat-
tributable for both patient and endpoint assessor.
Ethics, Consent, Study Organization and Registration
The trial will be conducted in agreement with the
principles of the Declaration of Helsinki, and with the
guidelines of Good Clinical Practice (GCP) of the
International Conference on Harmonisation of Techni-
cal Requirements for Registration of Pharmaceuticals
for Human Use (ICH). The study protocol was
approved by the local and independent Ethics Commit-
tee Tübingen (Institutional Review Board). Extramural
funding for the present study is provided by Medtronic
GmbH (Medtronic, Meerbusch, Germany). The investi-
gator will explain the benefits and risks of participation
in the study to each subject and will provide an
informed consent form approved by the independent
ethics committee. Only patients, who sign the form,
will be included in the study. Results will be published
anonymously. If there is an unexpected worsening of
motor or neuropsychiatric symptoms, patients can
immediately contact our clinic 24 hours a day and will
be immediately referred to a neurologist specialised on
deep brain stimulation.
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Data Management
Case report forms must be completed according to the
following schedule:
a) Before the treatment starts: the patient must be
screened/randomised. For that purpose all relevant data
must be reported.
b) Documentation of the treatment and follow-up vis-
its: Each visit should be documented immediately.
c) Upon occurrence of a Severe Adverse Event (SAE)
All SAEs occurring during the observation period of 9
months must be reported by fax to the sponsor’s medi-
cal expert, the medical director of the Department of
Neurodegenerative Diseases of the Center of Neurology,
Tuebingen University. All forms must be dated and
signed by the responsible investigator or one of his/her
authorized staff members.
All data will be documented on CRFs by authorized
investigators and monitored for completeness and cor-
rectness. Only complete and correct data will be entered
into the study data base. The study software koordobas,
an Oracle-based application of the department of Medi-
cal Biometry, will be used for the data management.
In all cases, it remains the responsibility of the investi-
gator to check that case report forms are completely
and correctly filled in. The data manager will perform
extensive consistency checks on the CRFs and issue
Query Forms in case of inconsistent data. Those Query
Forms must be immediately answered and signed by the
investigator (or an authorized staff member). The origi-
nal must be returned to the data manager and a copy
must be appended to the investigator’s copy of the
CRFs.
All study related data (electronic as well as on paper)
will be stored for 10 years in the archive of the Depart-
ment of Neurodegenerative Diseases of the Center of
Neurology, Tübingen University, University of
Tübingen.
Assessment, storing, processing, and deleting of per-
son related data will be conducted in accordance to
German law.
Discussion
The treatment of hypokinetic gait disturbances refrac-
tory to dopaminergic medication and conventional
STN-DBS constitutes an unmet therapeutic need with
important impact on quality of life. Current concepts
aim on neuromodulation of reciprocal functional loco-
motor circuitries of basal ganglia and brainstem that
hold an integrative key role within the locomotor sys-
tem. This double-blind controlled cross-over phase II
clinical trial has been designed to evaluate both short-
term and long-term efficacy of a novel stimulation para-
digm using ‘interleaved pulses’ on subthalamic and
nigral electrode contacts for refractory gait disturbances.
Based on the effect size and standard deviation of the
Intention-to-treat analysis a larger clinical efficacy study
will be designed.
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